Previous studies have validated the distribution and efficacy of these molecules in vivo and in vitro24; injection of 100 μg of each conjugate was sufficient to inhibit H2O2 or VEGF-induced endothelial permeability in vitro25, and ROS-induced pulmonary edema in vivo26. The gene discussed is VEGFA; the disease is pulmonary edema.